|
64 Companies |
|
21 Products |
|
21 Products |
|
23 Mechanisms of Action |
|
207 Trials |
|
10745 News |
|
| «12...6061626364656667686970...136137» |
- | Soliris (eculizumab) / AstraZeneca
Journal: Academic and Employment Status in Patients With Generalized Myasthenia Gravis Treated With Eculizumab: A Case Series. (Pubmed Central) - May 25, 2022
These results suggest that treatment with eculizumab may help maintain education/employment activity in patients with refractory generalized MG.
- ANTI-NEURONAL IGG4 AUTOIMMUNE DISEASES AND IGG4-RELATED DISEASES MAY NOT BE PART OF THE SAME SPECTRUM: A COMPARATIVE STUDY (ALEXANDRA TRIANTI) - May 25, 2022 - Abstract #AUTO2022AUTO_272;
Last, a kidney biopsy from a patient with autoimmune paranodopathy due to CNTN1/Caspr1-complex IgG4 autoantibodies and concomitant nephrotic syndrome did not show fibrosis or IgG4 + plasma cells, which are diagnostic hallmarks of IgG4-RLD. Conclusions Our observations suggest that anti-neuronal IgG4-AID and IgG4-RLD are most likely distinct disease entities.
- ANTIGEN-SPECIFIC TOLERANCE INDUCTION AS A THERAPY FOR MYASTHENIA GRAVIS (MC2 HALL) - May 25, 2022 - Abstract #AUTO2022AUTO_217;
Conclusions Restoring immunological tolerance against specific autoantigens by intravenous administration is, therefore, a promising therapeutic approach for MG. Further investigations are underway to elucidate immune mechanisms involved.
- NOVEL IMMUNOTHERAPIES FOR MYASTHENIA GRAVIS AND NEUROMYELITIS OPTICA (MC2 HALL) - May 25, 2022 - Abstract #AUTO2022AUTO_212;
- NEUROLOGICAL ADVERSE EVENTS OF IMMUNE CHECKPOINT INHIBITORS: DIVERSITY OF CLINICAL PRESENTATIONS AND OUTCOMES (MC2 HALL) - May 25, 2022 - Abstract #AUTO2022AUTO_121;
Conclusions These findings highlight the clinical heterogeneity of n-irAEs. Outcomes varied depending on both the initial clinical presentation and the occurrence of cancer progression.
- || Clinical, Journal, HEOR: Burden of disease in myasthenia gravis: taking the patient's perspective. (Pubmed Central) - May 25, 2022
P=N/A
The burden of MG on patients includes economic and social aspects as well as their emotional well-being. New therapies must achieve improvements for patients in these areas.
- || Clinical, Journal: Causes of symptom dissatisfaction in patients with generalized myasthenia gravis. (Pubmed Central) - May 25, 2022
The results emphasize the importance of a patient-centered approach to MG treatment to optimize patient satisfaction. The PASS question was useful in this study to investigate the causes of symptom dissatisfaction in gMG.
- || Clinical, Review, Journal: Utilization of MG-ADL in myasthenia gravis clinical research and care. (Pubmed Central) - May 25, 2022
The use of the MG-ADL as a primary endpoint in clinical trials and in responder threshold analyses to indicate treatment improvement has increased in recent years. MSE using the MG-ADL shows promise in helping to determine success of treatment and may be the aspirational goal of MG treatment for the future once validated, particularly given the evolving treatment landscape in MG.
- | Journal: Less is not necessarily more: low-dose corticosteroid therapy and long-term prognosis in generalized myasthenia gravis after thymectomy. (Pubmed Central) - May 25, 2022
Low-dose initiation, slowly incrementing PSL therapy is feasible for generalized MG patients after thymectomy. Early response to low-dose PSL therapy may predict better long-term outcomes.
- | Journal: Bedside and laboratory diagnostic testing in myasthenia. (Pubmed Central) - May 25, 2022
Newer testing strategies that have been investigated over the last couple of decades include ocular vestibular-evoked myogenic potentials, otoacoustic emissions and disease-specific circulating miRNAs in serum for autoimmune myasthenia, as well as next-generation sequencing for genetic testing of CMS. While there has been significant progress in developing newer testing strategies for diagnosing MG and CMS over the last couple of decades, more research is needed to assess the utility of these newer tools regarding their sensitivity and specificity.
- | Reimbursement, Journal, Medicare: Validation of myasthenia gravis diagnosis in the older Medicare population. (Pubmed Central) - May 25, 2022
While there has been significant progress in developing newer testing strategies for diagnosing MG and CMS over the last couple of decades, more research is needed to assess the utility of these newer tools regarding their sensitivity and specificity. Algorithms using ICD codes can reliably identify patients with MG with a high degree of accuracy.
- | Journal: The dispersion of individual jitter values is a sensitive diagnostic indicator of voluntary SFEMG. (Pubmed Central) - May 25, 2022
Algorithms using ICD codes can reliably identify patients with MG with a high degree of accuracy. No abstract available
- ||| Journal, Adverse events: The difficulty of confirming pharmacovigilance signals in myasthenia gravis. (Pubmed Central) - May 25, 2022
No abstract available No abstract available
- | Journal: Expanding the spectrum of SOX1-antibodies in neuropathy: the coexistence of anti-SOX1 and Guillain-Barré syndrome-a case report. (Pubmed Central) - May 25, 2022
Although the concept of paraneoplastic GBS is controversial, different cases have been reported and GBS is considered a non-classical paraneoplastic syndrome. Our case expands the anti-SOX1-antibody clinical spectrum with relevant implications for the clinical practice.
- | Retrospective data, Journal: Analysis of clinical characteristics and related genetic variation of juvenile myasthenia gravis (Pubmed Central) - May 25, 2022
The incidence of juvenile MG was preschoolers with no gender difference, and ocular MG was more common. The proportion of TTN gene variation in adolescent MG was higher, suggesting that this gene may be a potential therapeutic target for juvenile MG patients.
- | Journal: Educational Case: Lambert-Eaton syndrome. (Pubmed Central) - May 24, 2022
The proportion of TTN gene variation in adolescent MG was higher, suggesting that this gene may be a potential therapeutic target for juvenile MG patients. No abstract available
- | Journal: Autoimmune Disease in Patients With Advanced Thymic Epithelial Tumors. (Pubmed Central) - May 24, 2022
Patients who developed AD other than myasthenia gravis were more likely to do so several years after TET diagnosis. Additional work, including multiomic analyses, is needed to develop predictive markers for AD in advanced TET.
- || Review, Journal: Thymectomy in Myasthenia Gravis: A Narrative Review. (Pubmed Central) - May 24, 2022
However, thymectomy is yet controversial in some disease subtypes and there are potential concerns regarding the selection of the ideal surgical approach to achieve complete removal of the thymic tissue to achieve stable remission rates. This review highlights the role of thymectomy in non-thymomatous and thymomatous MG, the effectiveness of various thymectomy methods, postoperative myasthenic crisis, and remission after thymectomy.
- | Journal: LncRNA OIP5-AS1 modulates the proliferation and apoptosis of Jurkat cells by sponging miR-181c-5p to regulate IL-7 expression in myasthenia gravis. (Pubmed Central) - May 24, 2022
We confirmed that OIP5-AS1 serves as an endogenous sponge for miR-181c-5p to regulate the expression of IL-7. Our findings provide novel insights into MG processes and suggests potential therapeutic targets for patients with MG.
- INVESTIGATION OF THE TYPE AND FREQUENCY OF NEUROLOGICAL SIDE EFFECTS WITH BIOLOGICAL TREATMENT IN INFLAMMATORY RHEUMATIC DISEASES () - May 24, 2022 - Abstract #EULAR2022EULAR_4357;
Therefore, patients using biological agents should also be questioned and examined in terms of neurological symptoms, and further examination should be applied if necessary. No significant relationship was found between discontinuation of biological drugs and improvement/progression of neurological symptoms, and more comprehensive studies are needed.
- nipocalimab (M281) / J&J
STUDY DESIGN OF A PHASE 2/3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF NIPOCALIMAB, AN FcRn ANTAGONIST, IN WARM AUTOIMMUNE HEMOLYTIC ANEMIA (wAIHA) () - May 24, 2022 - Abstract #EULAR2022EULAR_4222;
A phase 2 study investigating nipocalimab in patients with gMG provided proof of concept for a phase 2/3 interventional study with nipocalimab in patients with wAIHA. This phase 2/3 study is currently enrolling in the USA and Europe.
- AGE RELATED DIFFERENCES IN NEUROPSYCHIATRIC MANIFESTATIONS AMONG SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS – A SINGLE RHEUMATOLOGY CENTRE EXPERIENCE IN MALAYSIA () - May 24, 2022 - Abstract #EULAR2022EULAR_3416;
This phase 2/3 study is currently enrolling in the USA and Europe. Seizure disorders is the commonest manifestations amongst SLE patients in our study group and there was no association between neuropsychiatric manifestation with the age group.
- Keytruda (pembrolizumab) / Merck (MSD)
KEYNOTE-365 cohort D: Pembrolizumab (pembro) plus abiraterone acetate (abi) and prednisone in chemotherapy (chemo)–naive patients with metastatic castration-resistant prostate cancer (mCRPC) (Green Area, Room 3) - May 23, 2022 - Abstract #EAU2022EAU_2851;
P1/2
Safety was generally consistent with the individual profiles of each agent. There was an increased incidence of grade 3/4 ALT/AST laboratory elevations than reported for individual agents.
- | Enrollment open, HEOR, Surgery: RATS: Comparison of Single Port and Two Ports Robotic Assisted Thoracic Surgery for Thymectomy (clinicaltrials.gov) - May 23, 2022
P=N/A, N=60, Recruiting, Sponsor: Shanghai Pulmonary Hospital, Shanghai, China
There was an increased incidence of grade 3/4 ALT/AST laboratory elevations than reported for individual agents. Not yet recruiting --> Recruiting
- | Tecentriq (atezolizumab) / Roche
Journal: Myasthenia gravis induced by atezolizumab (Pubmed Central) - May 22, 2022
Not yet recruiting --> Recruiting No abstract available
- | Retrospective data, Journal: Refractory post-thymectomy myasthenia gravis with onset at MGFA stage V: a case report. (Pubmed Central) - May 21, 2022
Complete resection should be performed during thymectomy, if not, additional postoperative adjuvant therapy is neccessary to avoid recurrence. It's important to identify PTMG at a early stage, especially when being interfered with by postoperative complications, such as lung infection, so that treatments could be initiated as soon as possible to avoid developing to refractory PTMG.
- | Preclinical, Journal: Altered Metabolism of the Microbiota-Gut-Brain Axis Is Linked With Comorbid Anxiety in Fecal Recipient Mice of Myasthenia Gravis. (Pubmed Central) - May 21, 2022
Among three emotional brain regions, hippocampus was more affected. Therefore, disturbances in gut microbiota may be involved in the progress of anxiety-like behavior in MG due to the MGB axis.
- | Journal: A case of uniportal VATS thymectomy for Thymoma associated with myasthenia gravis and toxic multinodular goiter. (Pubmed Central) - May 21, 2022
MG should always be suspected in a patient with thymoma. VATS thymectomy has been increasingly used to treat thymoma as it has several advantages over open surgery.
- | zimberelimab (AB122) / Arcus Biosci, Otsuka, Gilead
Journal: Concurrent Ocular Myopathy and Myasthenia Gravis After Zimberelimab Therapy in a Patient With Non-Small-Cell Lung Cancer. (Pubmed Central) - May 20, 2022
VATS thymectomy has been increasingly used to treat thymoma as it has several advantages over open surgery. No abstract available
- ||| Clinical: @DrCSWilliam 👋🏽 Random Question, but I’m doing more studies into COVID / health. Have you heard any major correlation between COVID and Myasthenia Gravis (MG)? (Twitter) - May 19, 2022
- | Journal: The use of frontalis sling in the management of variable ptosis secondary to congenital myasthenic syndrome. (Pubmed Central) - May 19, 2022
Blepharoptosis surgery in CMS patients with variable ptosis is difficult due to the risk of upsetting the original lid position and developing post-operative exposure keratopathy. Our case demonstrates that the frontalis sling procedure may be considered as an option in the management of variable blepharoptosis secondary to CMS.
- || Clinical, Journal: Acute exudative paraneoplastic polymorphous vitelliform maculopathy in a patient with thymoma, myasthenia gravis, and polymyositis. (Pubmed Central) - May 19, 2022
Three years prior, the patient had been diagnosed with polymyositis related to paraneoplastic syndrome; 1 year prior, she had been examined for pleural thickening due to suspected metastatic tumor. On her most recent follow-up visit at 3 months after initial diagnosis, the patient was stable with no clinically significant progression in ocular or systemic conditions.
- | Journal: Do people with Myasthenia Gravis need speech-language pathology services? A national survey of consumers' experiences and perspectives. (Pubmed Central) - May 19, 2022
These findings highlight unmet consumer needs for MG-related bulbar symptoms, and a lack of awareness of SLP services. It is suggested that, in addition to other strategies, consumer education and increased awareness are required to address these unmet needs.
- | Journal: The clinical need for clustered AChR cell-based assay testing of seronegative MG. (Pubmed Central) - May 18, 2022
In a complementary experiment, circulating AChR-specific B cells were identified in a CBA-positive SNMG patient. These findings corroborate the clinical need for clustered AChR CBA testing when evaluating SNMG patients.
- | New trial: Association Study Between VDR Gene Polymorphisms and Risk and Features of MG in Han Chinese Population (clinicaltrials.gov) - May 17, 2022
P=N/A, N=297, Completed, Sponsor: Beijing Tongren Hospital
- | Two Investigational Meds Promising for Myasthenia Gravis https://t.co/edZ6yxwVnv via @medscape (Twitter) - May 17, 2022
- | Trial completion: Diaphragm Thickness by Ultrasonography in Neurological Disorders (clinicaltrials.gov) - May 15, 2022
P=N/A, N=60, Completed, Sponsor: Mansoura University
These findings corroborate the clinical need for clustered AChR CBA testing when evaluating SNMG patients. Recruiting --> Completed
- |||| Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) / argenx
New P2/3 trial: Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis (clinicaltrials.gov) - May 15, 2022
P2/3, N=12, Not yet recruiting, Sponsor: argenx
- | Retrospective data, Journal: Lymphoplasma Exchange Improves Myasthenia Gravis Exacerbations: A Retrospective Study in a Chinese Center. (Pubmed Central) - May 15, 2022
Early use of LPE on early-onset MG may have good therapeutic effects. The potential mechanism for LPE is the polarization of cytokines from IL-17A, IFN-γ, into IL-10.
- || prednisone / Generic mfg.
Review, Journal: Corticosteroid Treatment-Resistance in Myasthenia Gravis. (Pubmed Central) - May 14, 2022
Chronic, high-dose, oral prednisone has been the mainstay of myasthenia gravis treatment for decades and has proven to be highly beneficial in many, toxic in some way to all, and not effective in a significant minority...Treatment response may be limited because disease mechanisms are not influenced by corticosteroids, limits on dosage because of adverse effects, or individual differences in corticosteroids. This review evaluates potential mechanisms that underlie lack of response to glucocorticoids in patients with myasthenia gravis.
- | Journal: Lack of Immunotherapy as the Only Predictor of Secondary Generalization in Very-Late-Onset Myasthenia Gravis With Pure Ocular Onset. (Pubmed Central) - May 14, 2022
Altogether, compared to the patients with very-late-onset GMG, the counterparts with OMG exhibit a significantly higher female predominance and a lower positive rate of RNS tests, especially on facial and accessory nerves. Lack of immunotherapy is the only predictor of secondary generalization in those with pure ocular onset.
- | CP010 / AstraZeneca
Preclinical, Journal: Development, Characterization, and in vivo Validation of a Humanized C6 Monoclonal Antibody that Inhibits the Membrane Attack Complex. (Pubmed Central) - May 14, 2022
CP010 is a promising complement C6 inhibitor that prevents MAC formation. Systemic administration of this C6 monoclonal antibody has therapeutic potential in the treatment of neuronal disease.
- Ultomiris IV (ravulizumab IV) / AstraZeneca
A REAL-WORLD ANALYSIS OF HEALTHCARE RESOURCE UTILIZATION AMONG PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO RECEIVED TREATMENT WITH RAVULIZUMAB () - May 13, 2022 - Abstract #EHA2022EHA_2324;
This suggests improvements in Hb may be an important driver of morbidity and costs among patients with PNH. These findings also highlight the utility of improved Hb levels as a metric for assessing the PNH treatment response.
- efgartigimod SC (ARGX-113 SC) / argenx, Vyvgart (efgartigimod alfa-fcab) / argenx, Broteio
EFGARTIGIMOD: CLINICAL DEVELOPMENT OF A NOVEL FCRN ANTAGONIST IN THE TREATMENT OF AUTOIMMUNE DISEASES () - May 13, 2022 - Abstract #EHA2022EHA_2224;
In all studies to date, EFG was well tolerated, and adverse events were mainly mild to moderate. Conclusion FcRn inhibition by EFG is a promising potential therapeutic option for several autoimmune diseases mediated by pathogenic IgG autoantibodies.
- Soliris (eculizumab) / AstraZeneca, ABP 959 (eculizumab biosimilar) / Amgen
PHARMACOKINETIC AND PHARMACODYNAMIC SIMILARITY OF ABP 959 AND ECULIZUMAB REFERENCE PRODUCT: UNBOUND ECULIZUMAB AND CH50 FROM THE RANDOMIZED, DOUBLE-BLIND, SINGLE-DOSE STUDY IN HEALTHY VOLUNTEERS () - May 13, 2022 - Abstract #EHA2022EHA_1121;
Conclusion These additional clinical pharmacology results demonstrate bioequivalence of ABP 959 to eculizumab RP with regard to unbound eculizumab and CH50. These results further support the PK/PD similarity of ABP 959 with eculizumab RP.
- efgartigimod SC (ARGX-113 SC) / argenx, Vyvgart (efgartigimod alfa-fcab) / argenx, Broteio
Efgartigimod: A Novel FcRn Antagonist in the Treatment of Autoimmune Diseases (Exhibition) - May 13, 2022 - Abstract #ISTH2022ISTH_373;
In a Phase 2 trial in ITP, EFG dosed at 5 and 10 mg/kg weekly for 4 weeks reduced IgG by ~60%, leading to clinically relevant increases in platelet counts (46% of EFG patients vs 25% on placebo achieved a platelet count of ≥50 × 109/L on ≥2 occasions). Phase 2/3 studies in CIDP (ADHERE), PV/PF (ADDRESS), BP (BALLAD), and myositis (ALKIVIA) are ongoing.
- | Journal: Pregnancy and Autoimmune Disease: Diseases of the Nervous System, Connective Tissue, and the Bowel. (Pubmed Central) - May 12, 2022
The care of pregnant women with chronic diseases requires collaboration between specialists of the pertinent levels of care. A stable course of disease before conception, close interdisciplinary care, and pregnancy-compatible medication contribute to a reduction in maternal and perinatal complications.
- | Journal: DOK7 congenital myasthenic syndrome responsive to oral salbutamol. (Pubmed Central) - May 12, 2022
A stable course of disease before conception, close interdisciplinary care, and pregnancy-compatible medication contribute to a reduction in maternal and perinatal complications. No abstract available